Major Events

Procter and Gamble Company and Teva Pharmaceutical Industries

The Procter & Gamble Company and Teva Pharmaceutical Industries

Nov 3, 2011

New Joint Venture, to be named “PGT Healthcare,” has the potential to reach double-digit sales growth and $4 billion in sales towards end- of- decade

CINCINNATI, OH and JERUSALEM, ISRAEL, November 3, 2011 – The Procter & Gamble Company (NYSE: PG) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced the creation of a new partnership and joint venture (JV) in consumer health care. The JV, to be named PGT Healthcare, will be headquartered in Geneva, Switzerland and will operate in essentially all markets outside of North America. The partnership between P&G and Teva will also develop new brands for the North American market.

 

PGT Healthcare, a new model in the industry, will focus on best-in-class development and state-of-the-art commercialization of branded OTC medicines. The JV will bring together each company’s complementary capabilities and existing over-the-counter (OTC) medicines. As a result, PGT Healthcare expects to accelerate growth for its parent companies and compete for leadership in the fast-growing, $200 billion consumer healthcare industry. The partnership will start from a solid base of approximately $1.3 billion in annual sales with the potential to grow to $4 billion in annual sales towards the end of the decade.

 

“This unique and transformational partnership creates one of the broadest and deepest OTC product portfolios and geographic footprints in the industry,” said Shlomo Yanai, Teva’s President and Chief Executive Officer. “Each company’s leading brands will experience tremendous growth by combining our strengths. We will be better together.”

 

Combined Capabilities for Faster Growth

PGT Healthcare blends both companies’ core strengths and capabilities to facilitate rapid expansion into new countries and categories. P&G and Teva believe the combination of each company’s strengths positions the JV well for double-digit sales growth - ahead of the market and beyond what each company alone was expecting to deliver.

 

“P&G’s partnership with Teva creates a combined set of capabilities that is unmatched in the industry, ” said Bob McDonald, Chairman of the Board, President and Chief Executive Officer of P&G. “Starting today our combined consumer health care business will now offer more branded OTC products to more consumers in more parts of the world.”

 

 

World’s Leading Seller of Medicines and World’s Leading Brand-Builder Coming Together

 

World’s Leading Seller of Medicines and World’s Leading Brand-Builder Coming Together
 

 

Entry into More Markets, More Categories
To begin accelerating growth immediately, and to reach the potential $4 billion in annual sales towards the end of the decade, with continuous strong growth beyond, the companies plan to:
  • Optimize the base business of approximately $1.3 billion in sales by joining each company’s industry-leading capabilities with the other company’s existing brands and operations.  P&G will bring best-in-class consumer understanding, branding, design, and in-store merchandising to Teva’s leading brands, such as ratiopharm.  Teva will bring deeper, broader pharmacy distribution, including its pharmacy sales force and strong pharmacy relationships, broader regulatory capabilities and new technologies to P&G’s leading brands, which include Vicks, Metamucil and Pepto-Bismol.​​
  • Expand the product and brand portfolio of each company’s current businesses into more of the largest, fastest-growing countries in the OTC industry.  Teva and P&G’s combined geographic footprint will now cover most key markets.  Among the largest, fastest growing OTC markets in the world, P&G has a strong presence in the U.S., Canada, Brazil, Mexico, India, Indonesia, Australia, Italy, France and the UK.  Teva is strong in Russia, Poland, Ukraine, Germany, Japan, the Scandinavian countries, Venezuela, Chile, Peru and Israel.  PGT will leverage the combined capabilities to expand into whitespaces such as China.  Additionally, some of the existing Teva brands are local leaders and offer global or regional expansion potential.
  • Expand into new OTC categories.  Today, P&G has a strong category presence in cough/cold, digestive wellness and women’s diagnostics.  Teva’s portfolio includes many technologies and leading brands in other key OTC categories such as vitamins, minerals and supplements, analgesics, medicated skin, and potential Rx-to-OTC switches.  Several of the existing Teva brands are local leaders and offer global or regional expansion potential.  Further, some of Teva’s technologies can be used almost immediately to expand P&G’s portfolio into new sub-categories all around the globe, including in the US.  For example, Teva’s technology portfolio includes most of the world’s leading allergy compounds.  This could enable the expansion of Vicks into allergy treatment.
  • Drive scale and cost synergies by leveraging each company’s industry leading scale and operational efficiencies. For example, P&G will bring media purchasing synergies to the venture given its position as the world’s leading advertiser.  Teva will bring scale and efficiency to product development and manufacturing, capitalizing on its position as the leading supplier of medicines worldwide.

 

PGT Healthcare will be led by a management team comprised of experienced senior leaders from both companies, including CEO Briain de Buitleir from P&G, and COO Eli Shani from Teva Pharmaceutical Industries.  A supervisory board representing both parent companies will govern the venture.  Tom Finn, P&G’s President of Global Health Care, will be chairman of this supervisory board.

 

In connection with the formation of this JV, P&G has sold its OTC plants in Greensboro, North Carolina (Vicks production) and Phoenix, Arizona (Metamucil production) and transferred the employees of both plants to Teva.  As part of the partnership, Teva will be the manufacturer and supplier for the PGT Healthcare business and P&G’s North American OTC business.

 

 

About Procter & Gamble

P&G touches and improves the lives of about 4.4 billion people around the world with its
portfolio of trusted, quality brands.  The Company's leadership brands include Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Mach3®, Bounty®, Dawn®, Fairy®,
Gain®, Pringles®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Oral-B®, Duracell®, Olay®, Head & Shoulders®, Wella®, Gillette®, Braun®, Fusion®, Ace®, Febreze®, and Ambi Pur®.  With operations in about 80 countries, P&G brands are available in more than 180 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

 

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.